Oncology
Pharma,
Inc. Prepares
Plan Toward
Funding
Development and Implementation
of Ribera
Solutions' Patient Engagement and Retention Platform
San Francisco,
CA -- April 21, 2021 -- InvestorsHub NewsWire
-- Oncology
Pharma Inc. (OTC:
ONPH) Oncology
Pharma, Inc. (the
"Company") is moving
ahead with advancing its efforts with Ribera Solutions' Conect2Med
platform with Oncology
Pharma's exclusivity for oncology, including drug development,
clinical trials, personalized oncology and
therapeutics.
Ribera has
been developing its platform and Oncology Pharma,
under its
License Agreement,
is
preparing
the necessary steps to proceed to advance the development and
implementation.
Connect2Med is
a patient engagement and retention platform designed to improve the
clinical trial experience for both patients and
providers. With Connect2Med, sponsors, CROs, and sites have a place
for leads, or people in their databases, to "live" in an online
community. The
platform
provides a private, secure space where people interested in or
recruited to clinical trials have a safe, closed community they can
join that provides trustworthy information and compassionate
connections to support them on their journey.
Connect2Med
provides a motivating trial experience through increased engagement
and easy to use communication tools. They have access to a
dedicated trial specific portal (patient facing app), where they
can perform functions like eDiary,
ePRO, telehealth visits. The platform is FHIR compatible and easily
integrates with EHR, CTMS, CRM from major vendors in the industry.
Patients' workflow can be automated through a set of digital
workflows, with automated interventions and escalation when needed.
Sites and CROs can post upcoming trials in a public space for all
to see, boosting public awareness through social sharing. Site
owners and Sponsors have access to impactful data, metrics and
reports that allow them to make strategic decisions to improve
retention, growth, performance, satisfaction and ROI.
ABOUT ONCOLOGY PHARMA, INC.
ONCOLOGY
PHARMA, INC. (OTCPK:
ONPH) (the "Company") is currently engaging in research and
development of therapeutics for oncology and prides itself for
having a world-class Advisory Board that keeps the Company in the
forefront of developing technologies in cancer research,
biotechnology, and healthcare.
ABOUT Ribera Solutions, LLC (www.riberasolutions.com)
Ribera
Solutions (CA, USA) has developed Web based Connect2Med platform
with iOS and Android mobile Apps. Ribera's mission is to provide
solutions for solving challenging problems timely through simple,
practical and economical approaches.
FORWARD LOOKING STATEMENTS
Certain of the
matters discussed in this announcement contain forward-looking
statements that involve material risks to and uncertainties in the
Company's business that may cause actual results to differ
materially from those anticipated by the statements made herein.
Such risks and uncertainties include risks related to licensing
arrangements and joint ventures, including the need to negotiate
the definitive agreements for the relationships; possible failure
to realize anticipated benefits of business relationships; and,
costs of providing funding to these business relationships. Other
risks and uncertainties relating to the Company include, among
other things, current negative operating cash flows and a need for
additional funding to finance our operating plan; the terms of any
further financing, which may be highly dilutive and may include
onerous terms; unexpected costs and operating deficits, and lower
than expected sales and revenues; uncertain willingness and ability
of customers to adopt new technologies and other factors that may
affect further market acceptance; adverse economic conditions;
adverse results of any legal proceedings; the volatility of our
operating results and financial condition; inability to attract or
retain qualified senior management personnel, including sales and
marketing personnel; our ability to establish and maintain the
proprietary nature of our technology through the patent process, as
well as our ability to possibly license from others patents and
patent applications necessary to develop products; the Company's
ability to implement its long range business plan for various
applications of its technology; the Company's ability to enter into
agreements with any necessary marketing and/or distribution
partners and with any strategic or joint venture partners; the
impact of competition; the obtaining and maintenance of any
necessary regulatory clearances applicable to applications of the
Company's technology; management of growth; and, other risks and
uncertainties. This is not a solicitation to buy or sell securities
and does not purport to be an analysis of the Company's financial
position.
CONTACTS:
For additional
Information, please contact the Oncology Pharma at:
One Sansome
Street, Suite 3500
San Francisco,
CA 94104
Phone:
415-869-1038
Fax:
415-946-8801
website: www.oncology-pharma.com
email:
info@oncology-pharma.com